BioCentury | Jul 24, 2019
Company News

July 23 Company Quick Takes: FDA approves Pfizer’s Rituxan biosimilar; plus Intra-Cellular, OTC Tamiflu, Cimzia and more

Pfizer’s Rituxan biosimilar approved in U.S. FDA approved Ruxience rituximab-pvvr from Pfizer Inc. (NYSE:PFE) for non-Hodgkin lymphoma, chronic lymphocytic leukemia and granulomatosis with polyangitis and microscopic polyangitis. Ruxience is the second biosimilar of Rituxan, an...
BioCentury | Feb 8, 2019
Company News

Sanofi seeking partner to develop Oxford BioMedica's ophthalmology gene therapies

Oxford BioMedica plc (LSE:OXB) said Sanofi (Euronext:SAN; NASDAQ:SNY) will seek a partner to continue further development of two ophthalmology gene therapy programs that the pharma gained under a 2009 deal with Oxford BioMedica. The products...
BioCentury | Sep 14, 2018
Product R&D

Academia’s manufacturing problem

...of its programs generated animal data showing it could slow loss of sight caused by USH1C...
...declined to specify the source of Odylia’s other four disclosed programs, which deliver the genes USH1C...
...Retinol dehydrogenase 12 RPGRIP1 - Retinitis pigmentosa GTPase regulator interacting protein 1 USH1C - Usher syndrome 1C...
BioCentury | Aug 10, 2018
Finance

Sound story

...School showed that, in a mouse model of Usher Syndrome, the Anc80L65 vector could deliver Usher syndrome 1C (USH1C)...
BioCentury | Aug 10, 2018
Financial News

Hearing loss play Akouos grabs $50M series A

...School researchers showed the Anc80L65 vector could target inner ear hair cells and deliver the Usher syndrome 1C (USH1C)...
BioCentury | Aug 7, 2018
Financial News

Hearing loss play Akouos grabs $50M series A

...School researchers showed the Anc80L65 vector could target inner ear hair cells and deliver the Usher syndrome 1C (USH1C)...
BioCentury | Dec 8, 2017
Company News

Akouos licenses gene therapy tech from Massachusetts Eye and Ear

...School researchers showed the Anc80L65 vector could target inner ear hair cells and deliver the Usher syndrome 1C (USH1C)...
...Otologic, Gene/Cell therapy Mary Romeo 5AM Ventures Akouos Inc. Lonza Group Ltd. Massachusetts Eye and Ear New Enterprise Associates Selecta Biosciences Inc. Vivet Therapeutics Usher syndrome 1C (USH1C)...
BioCentury | Dec 1, 2017
Company News

Akouos in-licenses gene therapy vectors from Mass. Eye and Ear

...School researchers showed the Anc80L65 vector could target inner ear hair cells and deliver the Usher syndrome 1C (USH1C)...
...2) . Mary Romeo 5AM Ventures Harvard Medical School Lonza Group Ltd. Massachusetts Eye and Ear New Enterprise Associates Selecta Biosciences Inc. Vivet Therapeutics Usher syndrome 1C (USH1C)...
BioCentury | Oct 4, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: September 2017

New Therapeutic Targets and Biomarkers: September 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during September 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Sep 14, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2017

New Therapeutic Targets and Biomarkers: August 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during August 2017. Therapeutic targets are defined as any protein, gene or other...
Items per page:
1 - 10 of 29